Comparison of Pulmonary Vein Ablation With or Without Left Atrial Posterior Wall Ablation for Persistent AF (PIVoTAL)
Status: | Recruiting |
---|---|
Conditions: | Atrial Fibrillation |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 9/7/2018 |
Start Date: | February 24, 2017 |
End Date: | December 2019 |
Contact: | Arash Aryana, MD |
Email: | a_aryana@outlook.com |
Phone: | 916-453-2684 |
Left Atrial Posterior Wall Isolation in Conjunction With Pulmonary Vein Isolation for Treatment of Persistent Atrial Fibrillation (PIVoTAL) Trial
The purpose of this study it to learn whether pulmonary vein isolation (PVI) along with
ablation of the posterior left atrial wall (PLAW) will reduce the likelihood of atrial
fibrillation (AF) recurrence in patients with persistent or long-standing persistent AF one
year after an ablation procedure in comparison to a PVI ablation procedure, alone.
The investigator hypothesizes that the combination of PVI plus PLAW isolation will result in
a reduction in recurrence of atrial arrhythmias at one year after ablation.
ablation of the posterior left atrial wall (PLAW) will reduce the likelihood of atrial
fibrillation (AF) recurrence in patients with persistent or long-standing persistent AF one
year after an ablation procedure in comparison to a PVI ablation procedure, alone.
The investigator hypothesizes that the combination of PVI plus PLAW isolation will result in
a reduction in recurrence of atrial arrhythmias at one year after ablation.
Patients with persistent or long-standing persistent atrial fibrillation will be enrolled in
this study. All patients are required to be in atrial fibrillation (AF) on the day of the
ablation procedure. After ablation (isolation) of the pulmonary veins (PVI) is complete, and
while still in the electrophysiology lab, all patients are randomized to either PVI, alone
[Group 1] or the combination of PVI plus ablation of the posterior left atrial wall (PLAW)
[Group 2]. For those patients randomized to PVI, their ablation procedure is complete at this
time. For those patients randomized to PVI plus PLAW, they will have the additional ablation
to the posterior left atrial wall performed.
All study patients have the same follow-up after their ablation procedure: clinic visits at
3, 6, and 13 months; a heart event monitor is worn for 7-14 days before these visits. An
echocardiogram is done at 4-6 months after the ablation procedure. Blood thinners are usually
recommended for three months after the ablation procedure and then the need for continued use
of blood thinners will be based on individual patient's medical history, stroke risk and the
judgement of their study doctor. Information about patient's medical history, heart
arrhythmias, and atrial fibrillation will be collected during the study. This information
will be analyzed as part of the study.
this study. All patients are required to be in atrial fibrillation (AF) on the day of the
ablation procedure. After ablation (isolation) of the pulmonary veins (PVI) is complete, and
while still in the electrophysiology lab, all patients are randomized to either PVI, alone
[Group 1] or the combination of PVI plus ablation of the posterior left atrial wall (PLAW)
[Group 2]. For those patients randomized to PVI, their ablation procedure is complete at this
time. For those patients randomized to PVI plus PLAW, they will have the additional ablation
to the posterior left atrial wall performed.
All study patients have the same follow-up after their ablation procedure: clinic visits at
3, 6, and 13 months; a heart event monitor is worn for 7-14 days before these visits. An
echocardiogram is done at 4-6 months after the ablation procedure. Blood thinners are usually
recommended for three months after the ablation procedure and then the need for continued use
of blood thinners will be based on individual patient's medical history, stroke risk and the
judgement of their study doctor. Information about patient's medical history, heart
arrhythmias, and atrial fibrillation will be collected during the study. This information
will be analyzed as part of the study.
Inclusion Criteria:
- Males and females with an age >18 years undergoing a first-time catheter ablation of
AF; prior ablation of a right atrial cardiac arrhythmia (i.e., typical right atrial
flutter) is permitted
- All patients must understand the requirements of the study and be willing to comply
with the post-study follow-up requirements
- Patients must be in AF on the day of the procedure
Exclusion Criteria:
- Any reversible cause of AF (post-operative, thyroid disorder, etc)
- Patients with cerebral ischemic events (stroke or transient ischemic attack),
myocardial infarction or unstable angina in the previous 2 months
- Patients with any corrected or uncorrected congenital heart disease
- Patients with a history of hypertrophic cardiomyopathy
- Patients with cardiomyopathy and a left ventricular ejection fraction <35%
- Congestive heart failure, class IV
- Women who are known to be pregnant or have had a positive β-HCG test 7 days prior to
procedure
- Patients whose life expectancy is <1 year
- History of left-sided left atrial ablation (catheter or surgically-based)
- Mental impairment precluding the patient from providing informed consent or completing
appropriate follow-up
We found this trial at
1
site
4001 J Street
Sacramento, California 95819
Sacramento, California 95819
Phone: 916-453-2684
Click here to add this to my saved trials